Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adds 76 mg every four weeks from week 49 for patients who maintained a response through at least 24 weeks of every-two-weeks treatment under the existing relapsed or refractory multiple myeloma indication.
LAMPGEN ANALYSIS
Why it matters
The extension can reduce clinic visits for patients with an established response while the original accelerated disease indication remains distinct.
What research teams should watch
Document response and time on prior dosing before spacing visits; maintain infection surveillance and clear instructions for dosing delays.
PRIMARY RECORDS